Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Elevar Therapeutics

Clinical trials sponsored by Elevar Therapeutics, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New pill targets rare cancer gene in 30-Patient trial Results expected Sep 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1 Completed 1 Terminated 1

New targeted pill shows promise for Hard-to-Treat bile duct cancers

Disease control Completed

This study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …

Phase 1/2 • Sponsor: Elevar Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 09:08 UTC